The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Consulting or Advisory Role - Abbvie; BeiGene; BMS GmbH & Co. KG; Incyte; Janssen; Kite/Gilead; Novartis; Regeneron; Roche; SOBI
Research Funding - BeiGene
Travel, Accommodations, Expenses - BeiGene; Regeneron; Roche
Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator’s choice in previously untreated follicular lymphoma (OLYMPIA-1).
 
Ruemu Ejedafeta Birhiray
Consulting or Advisory Role - Abbvie; Array BioPharma; Epizyme; Ipsen; Janssen Biologics BV; Janssen Scientific Affairs; Lilly; Regeneron (I); Sanofi; Takeda; TG Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; Blueprint Medicines; CTI; Daiichi Sankyo; E.R. Squibb Sons, LLC; Exelixis; Genzyme; Incyte; Janssen Biotech; Lilly; MorphoSys; Pharmacyclics; Puma Biotechnology; Regeneron; Sanofi; Seagen; SOBI; Stemline Therapeutics
 
Stefano Luminari
No Relationships to Disclose
 
Tae Min Kim
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; BeiGene; Daiichi Sankyo/Astra Zeneca; inno.N; Janssen Oncology; Novartis; Regeneron; Samsung Bioepis; Takeda
Speakers' Bureau - AstraZeneca/MedImmune; IMBdx; Janssen Research & Development; Takeda
(OPTIONAL) Uncompensated Relationships - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boryung (Inst); Dizal Pharma (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); Hanmi (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); RAPT Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst)
 
Münci Yağcı
Consulting or Advisory Role - Abbvie
 
Timothy Robert Wassenaar
No Relationships to Disclose
 
Ashish Risal
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Manjusha Namuduri
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Jingxian Cai
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron; Regeneron
Honoraria - Regeneron
Travel, Accommodations, Expenses - Regeneron
 
Bertha Fearon-Chalet
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Min Zhu
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Sushmita Mukherjee
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Jurriaan Brouwer-Visser
No Relationships to Disclose
 
Aafia Chaudhry
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Hesham Mohamed
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - Odronextamab related patents
 
Srikanth R Ambati
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Umberto Vitolo
Consulting or Advisory Role - Abbvie; Constellation Pharmaceuticals; Genmab; Gilead Sciences; Regeneron
Speakers' Bureau - Abbvie; Gilead Sciences; Incyte; Regeneron; Roche; SERVIER
Research Funding - Morphosys (Inst)
Travel, Accommodations, Expenses - Abbvie; Incyte